AJINDER DHATT: Open Payments
NPI 1851597793 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$803 in 39 payments from 9 companies in 2025. Trend: 2023 $407 · 2024 $749 · 2025 $803
Food & beverage: $803
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $319 |
| Axsome Therapeutics, Inc. | 2 | $137 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| E.R. Squibb & Sons, L.L.C. | 3 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
Products named: VRAYLAR, Auvelity, COBENFY, REXULTI, CAPLYTA, FANAPT, Qelbree, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
